PBE vs. SGVT

Last updated Jun 16, 2026

PBE (Invesco Dynamic Biotechnology & Genome ETF) and SGVT (Schwab Government Money Market ETF) are both exchange-traded funds - PBE is a Health & Biotech Equities fund tracking the Dynamic Biotech & Genome Intellidex Index (AMEX), while SGVT is a Money Market fund actively managed by Charles Schwab. PBE is passively managed, while SGVT is actively managed. Over the past year, PBE returned 34.13% vs 3.74% for SGVT. At a correlation of -0.01, they often move in opposite directions. PBE charges 0.59%/yr vs 0.28%/yr for SGVT.

Performance

PBE vs. SGVT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and Schwab Government Money Market ETF (SGVT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PBE achieves a 3.32% return, which is significantly higher than SGVT's 1.51% return.

PBE

• 1D: 0.81%
• 1M: 4.85%
• YTD: 3.32%
• 6M: 5.17%
• 1Y: 34.13%
• 3Y*: 10.91%
• 5Y*: 2.31%
• 10Y*: 8.90%

SGVT

• 1D: -0.01%
• 1M: 0.26%
• YTD: 1.51%
• 6M: 1.68%
• 1Y: 3.74%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PBE vs. SGVT - Yearly Performance Comparison

	2026 (YTD)	2025
PBE Invesco Dynamic Biotechnology & Genome ETF	3.32%	28.44%
SGVT Schwab Government Money Market ETF	1.51%	2.22%

Correlation

The correlation between PBE and SGVT is -0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.00
Correlation (All Time) Calculated using the full available price history since Jun 12, 2025	-0.01

Return for Risk

PBE vs. SGVT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBE

PBE Risk / Return Rank: 58
PBE Sharpe Ratio Rank: 58
PBE Sortino Ratio Rank: 63
PBE Omega Ratio Rank: 53
PBE Calmar Ratio Rank: 63
PBE Martin Ratio Rank: 52

SGVT

SGVT Risk / Return Rank: 100
SGVT Sharpe Ratio Rank: 100
SGVT Sortino Ratio Rank: 100
SGVT Omega Ratio Rank: 100
SGVT Calmar Ratio Rank: 100
SGVT Martin Ratio Rank: 100

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PBE vs. SGVT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and Schwab Government Money Market ETF (SGVT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	PBE	SGVT	Difference
Sharpe ratio: Return per unit of total volatility	1.81	18.33	-16.52
Sortino ratio: Return per unit of downside risk	2.68	100.91	-98.22
Omega ratio: Gain probability vs. loss probability	1.31	36.10	-34.79
Calmar ratio: Return relative to maximum drawdown	2.92	138.97	-136.05
Martin ratio: Return relative to average drawdown	8.21	1,477.41	-1,469.20

PBE vs. SGVT - Sharpe Ratio Comparison

The current PBE Sharpe Ratio is 1.81, which is lower than the SGVT Sharpe Ratio of 18.33. The chart below compares the historical Sharpe Ratios of PBE and SGVT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

PBE vs. SGVT - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, which is greater than SGVT's maximum drawdown of -0.03%. Use the drawdown chart below to compare losses from any high point for PBE and SGVT.

Drawdown Indicators

	PBE	SGVT	Difference
Max Drawdown Largest peak-to-trough decline	-45.69%	-0.03%	-45.66%
Max Drawdown (1Y) Largest decline over 1 year	-11.73%	-0.03%	-11.70%
Max Drawdown (3Y) Largest decline over 3 years	-22.43%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-34.71%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-37.84%	—	—
Current Drawdown Current decline from peak	-1.00%	-0.01%	-0.99%
Average Drawdown Average peak-to-trough decline	-16.21%	-0.00%	-16.21%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.17%	0.00%	+4.17%

Volatility

PBE vs. SGVT - Volatility Comparison

Invesco Dynamic Biotechnology & Genome ETF (PBE) has a higher volatility of 6.04% compared to Schwab Government Money Market ETF (SGVT) at 0.07%. This indicates that PBE's price experiences larger fluctuations and is considered to be riskier than SGVT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PBE	SGVT	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.04%	0.07%	+5.97%
Volatility (6M) Calculated over the trailing 6-month period	13.67%	0.13%	+13.54%
Volatility (1Y) Calculated over the trailing 1-year period	19.01%	0.21%	+18.80%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.48%	0.21%	+22.27%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.91%	0.21%	+24.70%

PBE vs. SGVT - Expense Ratio Comparison

PBE has a 0.59% expense ratio, which is higher than SGVT's 0.28% expense ratio.

Dividends

PBE vs. SGVT - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 1.02%, less than SGVT's 3.12% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
PBE Invesco Dynamic Biotechnology & Genome ETF	1.02%	1.00%	0.05%	0.02%	0.00%	0.00%	0.04%	0.00%	0.00%	0.57%	0.38%	1.12%
SGVT Schwab Government Money Market ETF	3.12%	1.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both PBE and SGVT in my portfolio?

PBE and SGVT have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PBE or SGVT?

PBE has higher volatility (6.04%) compared to SGVT (0.07%). In terms of maximum drawdown, PBE dropped -45.69% vs SGVT's -0.03%.

Which ETF is better, PBE or SGVT?

On 1-year performance, PBE leads with 34.13% vs 3.74% for SGVT. On fees, SGVT is cheaper at 0.28% per year. On volatility, SGVT has been the lower-risk option at 0.07%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, PBE or SGVT?

Over the 1-year period, PBE has performed better with a 34.13% return vs 3.74%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, PBE or SGVT?

SGVT is cheaper with a 0.28% expense ratio, compared with 0.59% for PBE.

Which ETF pays a higher dividend yield, PBE or SGVT?

SGVT has the higher dividend yield at 3.12%, compared with 1.02% for PBE.

What is the main difference between PBE and SGVT?

PBE is categorized as Health & Biotech Equities, while SGVT is Money Market. They also come from different issuers: Invesco and Charles Schwab. Their fees differ too: 0.59% for PBE and 0.28% for SGVT.

Which has better risk-adjusted returns?

SGVT currently has the higher Sharpe Ratio (18.33 vs 1.81), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.